ClinicalTrials.gg
CompletedNCT03176121STOP PainUpdated Mar 18, 2020

Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain

A Phase 4 interventional study of Oxycodone in Cancer and Pain, sponsored by Taiwan Mundipharma Pharmaceuticals Ltd.. Completed at 10 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.

Sponsored by Taiwan Mundipharma Pharmaceuticals Ltd. (part of Mundipharma) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2016, registered May 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

This study is to evaluate the safety and tolerability of oxycodone control-released (CR) and/or immediate-released (IR) use in patients with moderate to severe cancer pain in a 3-months period in Taiwan.

Read the detailed description

This is an open label, long-term study carrying in multi-centers. Around 200 patients with moderate to severe cancer pain (NRS ≥ 4) who agreed and signed informed consent will be enrolled to receive oxycodone with continuous around-the-clock pattern. The study is to evaluate the safety and tolerability of cancer patients who receive CR and/or IR oxycodone. The number and percentage of patients with adverse events and serious adverse events will be recorded throughout the study.

The study will continue for 3 months to observe the safety and tolerability. After screening at Screening visit, patients begin the study by the first day visit (Day 1). Pain assessment, study related questionnaires are giving out to measure the baseline scale of each patient. Questionnaires including rate of quality of analgesia, EQ-5D and clinical opiate withdrawal scale (COWS). The prescription of the study drug will be recorded from Day 1. Patients will need to visit bi-weekly, including Wk 2 (Day 14±3), Wk 4 (Day 28±3), Wk 6 (Day 42±3), Wk 8 (Day 56±3), Wk 10 (Day 70±3) and Wk 12 (Day 84±3). Pain assessment will be assessed in each visit, drug accountability will be recorded accordingly. The rate of quality of Analgesia will be assessed in each visit; QoL (EQ-5D) will be recorded in Wk 4, Wk 8 and Wk 12. The COWS will be assessed again in Wk 12.

The safety for individual patient will be followed during study up to 2 weeks after the end of treatment (EOT) or early termination (ET). The telephone contact for safety follow-up is acceptable for this study.

02

Conditions studied

  • Cancer
  • Pain

Keywords

  • Oxycodone
  • Cancer Pain
  • Long-term use
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 73 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Taiwan Mundipharma Pharmaceuticals Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cancer patients aged 20 years old and over
  2. ≤ 2
  3. Moderate to severe pain intensity (NRS pain score ≥ 4)
  4. Cancer-related pain that requires treatment with continuous around-the-clock strong opioid analgesic
  5. Patients who will not be treated with radiotherapy within 7 days prior to screening and during study
  6. Patients or his/her caregivers who are able to fill out the questionnaire forms
  7. Patient provided signed

Exclusion criteria

Exclusion Criteria:

  1. Patients diagnosed with non-cancer pain or unexplained pain
  2. Patients who cannot be applicable for oral administration
  3. Patients who have constipation ( grade 3 and above)
  4. Patients with evidence of significant structural/functional abnormalities of GI tract or planned to undergo surgeries that have high risk lead to gastrointestinal stenosis, blind loop or gastrointestinal obstruction during study
  5. Abnormal lab results, with obvious clinical significance, such as the creatinine ≥ 2 fold of value, or or AST ≥ 2.5 fold of upper limit of normal value (≥ 5 fold, to the patients with liver or primary liver cancer), or liver function of Child C grade prior to study
  6. Pregnant or nursing (lactating) women
  7. Patients who are drug or alcohol abuse
  8. Patients with moderate to severe psychiatric problems
  9. Patients who have to oxycodone
  10. Patients who are clinically unstable or have a of less than three months making completion of the trial unlikely
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Oxycodone treatment

    Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate his/her background dose. After regular time assessment of the pain score (NRS), if the pain control is inadequate (NRS ≥ 4), a total daily dose in 24hrs will be summed up for the next dose titration until reach a stable dose (as defined as total daily dose is fixed for at least two weeks).

    Drug: Oxycodone

Interventions

  • Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.

06

What researchers measure

Primary outcomes

  1. Number and percentage of patients with adverse events (AEs) and serious adverse events (SAEs)

    Number and percentage of patients with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to 14 weeks

Secondary outcomes

  1. Change from baseline pain intensity scale (NRS)

    The change from baseline pain intensity scale (NRS) to each visit

    Time frame: Up to 12 weeks

  2. Time (days) needs in first titration to a stable dose

    The time (days) needs in first stable titration

    Time frame: Up to 12 weeks

  3. Average dosage (mg/day) needs in first titration to a stable dose

    The average dosage needs in first stable titration

    Time frame: Up to 12 weeks

  4. Quality of analgesia using rating of excellent, very good, good, fair or poor

    The percentage of patients rating quality of analgesia of excellent, very good, good, fair or poor

    Time frame: Up to 12 weeks

  5. Treatment discontinuation reason (due to AE, withdraw consent, or any kinds of reasons)

    Analysis treatment discontinue reason (due to AE, withdraw consent, or any kinds of reasons)

    Time frame: Up to 12 weeks

  6. Change from baseline in QoL questionnaire (EQ-5D)

    The change from baseline in QoL questionnaire (EQ-5D)

    Time frame: Up to 12 weeks

  7. Opiate withdrawal level by Clinical Opiate Withdrawal Scale (COWS)

    The change of clinical opiate withdrawal scale (COWS) from baseline

    Time frame: Up to 12 weeks

  8. Safety and tolerability (PE and vital sign change from baseline)

    The change from baseline in PE and vital sign

    Time frame: Up to 14 weeks

07

Study locations

10 sites
  • Changhua Christian Hospital
    Chang-hua, 500, Taiwan
  • Chang Gung Memorial Hospital, Chiayi branch
    Chiayi City, Taiwan
  • Chang Gung Memorial Hospital, Kaohsiung branch
    Kaohsiung, 83301, Taiwan
  • Chang Gung Memorial Hospital, Keelung branch
    Keelung, 204, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • MacKay Memorial Hospital
    Taipei, 10449, Taiwan
  • Shin Kong Wu Ho-Su Memorial Hospital
    Taipei, 111, Taiwan
  • Tri-Service General Hospital
    Taipei, 114, Taiwan
  • Chang Gung Memorial Hospital, LinKou branch
    Taoyuan City, 333, Taiwan
08

References and documents

Publications

  • Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009 Aug;20(8):1420-33. doi: 10.1093/annonc/mdp001. Epub 2009 Feb 24. PubMed 19244085 ↗
  • Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012 Feb;13(2):e58-68. doi: 10.1016/S1470-2045(12)70040-2. PubMed 22300860 ↗
  • Ahmedzai SH, Leppert W, Janecki M, Pakosz A, Lomax M, Duerr H, Hopp M. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015 Mar;23(3):823-30. doi: 10.1007/s00520-014-2435-5. Epub 2014 Sep 14. PubMed 25218610 ↗
  • Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007 Jul;61(7):1181-7. doi: 10.1111/j.1742-1241.2007.01415.x. Epub 2007 May 4. PubMed 17488292 ↗
  • Mueller-Lissner S. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Ther. 2010 Sep;27(9):581-90. doi: 10.1007/s12325-010-0057-y. Epub 2010 Aug 11. PubMed 20714946 ↗
  • Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer. 1998 Jul;6(4):356-64. doi: 10.1007/s005200050177. PubMed 9695203 ↗
  • Kalso E. Oxycodone. J Pain Symptom Manage. 2005 May;29(5 Suppl):S47-56. doi: 10.1016/j.jpainsymman.2005.01.010. PubMed 15907646 ↗
  • Leppert W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep. 2010 Jul-Aug;62(4):578-91. doi: 10.1016/s1734-1140(10)70316-9. PubMed 20884999 ↗
  • Stessel B, Theunissen M, Fiddelers AA, Joosten EA, Kessels AG, Gramke HF, Marcus MA. Controlled-release oxycodone versus naproxen at home after ambulatory surgery: a randomized controlled trial. Curr Ther Res Clin Exp. 2014 Nov 28;76:120-5. doi: 10.1016/j.curtheres.2014.10.001. eCollection 2014 Dec. PubMed 25516773 ↗
  • Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage. 1999 Oct;18(4):271-9. doi: 10.1016/s0885-3924(99)00079-2. PubMed 10534967 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Dec 2018, 26 months.

Of 88 phase 4 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 64. This study's 26 months is below that.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2017
First posted
Jun 5, 2017
StartActual
Oct 31, 2016
Primary completionActual
Dec 31, 2018
CompletionActual
Dec 31, 2018
Last update
Mar 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03176121
Responsible party
Sponsor
First posted
Jun 5, 2017
Start date
Oct 31, 2016
Primary completion
Dec 31, 2018
Completion
Dec 31, 2018
Last update
Mar 18, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion